Objective-Monocyte/macrophage inflammation is an important contributor to diabetes and cardiovascular disease.
I n vitro and animal studies have implicated chronic inflammation in the development and progression of insulin resistance and type 2 diabetes, and in the excess cardiovascular disease risk associated with diabetes. 1 These findings closely parallel results from epidemiological studies that demonstrate plasma inflammatory markers (such as the acute phase proteins, C-reactive protein and serum amyloid A, and the proinflammatory cytokines, IL-6, IL-1␤, and possibly tumor necrosis factor-␣) as predictors, and potential mediators, of these conditions. [1] [2] [3] 
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Monocytes and macrophages are critical cells in the development of insulin resistance and cardiovascular disease. They accumulate early in atherosclerotic lesion development and remain throughout the transition to advanced atheroma. 4 They are closely linked to the chronic inflammatory processes that underlie plaque formation. Similarly, macrophages and macrophage-derived proinflammatory factors have been detected in adipose and other tissues 5 and appear to contribute to development of insulin resistance and hyperglycemia. 6, 7 Determining what factors play important roles in activating monocytes/macrophages and contribute to systemic inflammation is essential to understanding the pathophysiology of insulin resistance and cardiovascular disease.
Bacterial lipopolysaccharide (LPS) is a potent inducer of inflammation in many cell types via activation of Toll-like receptor (TLR)-4. TLR4 activity is mediated in large part by the transcription factor NF-B, a known regulator of Ͼ200 proinflammatory genes. 8 LPS is frequently present in low concentrations in blood, resulting from its release by the bacterial flora of the intestines, from subclinical infections, and from the presence of LPS in food. Plasma LPS is further elevated in the settings of obesity, insulin resistance, and type 2 diabetes, as well as during the postprandial period, especially after high-fat meals. 9, 10 Although these low concentrations of LPS do not appear to cause acute systemic inflammation, several lines of investigation have implicated TLR signaling in chronic inflammatory disease processes. Recent studies have demonstrated that mice lacking TLR4 or related signaling components, such as MyD88, have reduced susceptibility to atherosclerosis. [11] [12] [13] Furthermore, Cani et al 9 have demonstrated that subacute LPS elevations cause inflammation, initiate insulin resistance, and even contribute to obesity in animals.
TLR also recognize numerous endogenous molecules. Studies by Hwang, Flier, and others 14 -16 have suggested that elevated concentrations of saturated fatty acids (SFA) lead to activation of TLR2 and TLR4. Because Western diets are typically enriched in SFA, excess nutritional intake may increase plasma and tissue SFA concentrations, potentially inducing inflammation and contributing to development of insulin resistance. 17 Reduced insulin action increases adipose tissue lipolysis and hepatic production of triglyceride-rich lipoproteins, this may further increase concentrations of plasma free fatty acids (FFA), including SFA, Therefore, elevated plasma concentrations of SFA may facilitate the initiation and progression of insulin resistance 18 -20 and, through this mechanism, as well as direct vascular inflammation, contribute to development of diabetes and cardiovascular disease. 21 We have previously demonstrated direct proinflammatory effects of mixtures of FFA, as well as physiologically relevant concentrations of SFA, on human monocytes and macrophages in vitro, consistent with low-level activation of TLR by SFA. 22, 23 However, recent studies have called into question the ability of TLR to directly bind SFA as a ligand and suggest that SFA might modulate TLR activity via lipid raft changes 24 or that SFA may not induce inflammation via TLRmediated signaling at all. 25 We now describe the novel finding that SFA greatly amplify the proinflammatory cytokine responses of human monocytes and macrophages to low, physiologically relevant concentrations of LPS through a mechanism separate from, but parallel to, the TLR4 signaling pathway.
Materials and Methods
In typical experiments, cells (monocytes and macrophages) were exposed to FFA, LPS, specific pharmacological inhibitors, or combinations of these reagents. Cells were typically incubated with FFA or inhibitors for 16 hours, washed in phosphate-buffered saline, and resuspended in fresh media with or without 1 ng/mL Escherichia coli LPS for 30 minutes (for phosphoprotein assays), 4 hours (for real-time polymerase chain reaction), or 48 hours (for conditioned media enzyme-linked immunosorbent assay). Analysis of monocyte inflammation and gene expression was performed using standard laboratory methods or commercially available kits. For detailed materials and methods, see the online Supplementary material available at http://atvb.ahajournals.org.
Results
Compared to control cells, THP-1 monocytes exposed to 1 ng/mL LPS for 4 hours exhibited a 21-fold increase in IL-6 mRNA expression and a 10-fold increase in IL-8 mRNA expression ( Figure 1A ). Exposure of these cells to 100 mol/L palmitic acid (PA) for 16 hours induced a 7-fold and 2-fold increase in mRNA for these 2 cytokines, respectively. However, exposure of the cells to PA followed by LPS resulted in an 80-fold increase in IL-6 and a 53-fold increase in IL-8 mRNA expression, compared to controls. These results were significantly (PϽ0.05) higher than the sum of the separate effects of PA and LPS. Confirmatory experiments with other saturated ( Figure 1A ) and unsaturated fatty acids, and with both macrophages and primary human monocytes, are described elsewhere (see Supplementary Results and SupplementaryFiguresI,II,availableathttp://atvb.ahajournals. org). Similar to LPS, PA-induced amplification of the mono-cyte response to the TLR2 ligand Pam3CSK4 was also observed (Supplemental Figure III) .
Exposure of monocytes to SFA also enhanced LPS-induced secretion of cytokine proteins. Compared to controls, monocytes exposed to PA for 16 hours demonstrated increased IL-6 protein secretion over the subsequent 48 hours ( Figure 1B ). Exposure of monocytes to 1 ng/mL LPS alone for 48 hours did not increase IL-6 protein secretion. In contrast, exposure of monocytes to PA followed by LPS increased IL-6 protein secretion by nearly 4-fold; similar fold increases were observed for IL-8. These protein changes confirm the existence of the synergistic increase in inflammation that was suggested by mRNA responses. Although there was a detectable increase in IL-6 and IL-8 mRNA in response to 4 hours of LPS treatment alone, protein secretion in response to 48 hours of LPS alone was not different from controls. In contrast, pretreatment with PA induced a A, THP-1 monocytes were exposed for 16 hours to media alone (C) or to media containing 100 mol/L lauric acid (LaA), palmitic acid (PA), or stearic acid (SA); to 1 ng/mL LPS (LPS) for 4 hours; or to LaA, PA, or SA followed by LPS (LaA LPS, PA LPS, or SA LPS, respectively). IL-6 (white bars) and IL-8 (black bars) mRNA was measured by real-time polymerase chain reaction. B, THP-1 monocytes were exposed to PA or LPS as in (A) for a total of 20 hours, then they were washed and incubated in fresh growth media for 48 hours. IL-6 and IL-8 proteins secreted into these conditioned media were measured by enzyme-linked immunosorbent assay. Data are meanϮSEM; nՆ4. *PϽ0.05 vs LPS alone and vs the respective fatty acid alone.
prolonged and detectable increase in LPS-stimulated IL-6 and IL-8 protein secretion.
To elucidate the underlying mechanism by which SFA amplifies monocyte inflammation, we evaluated and excluded several possibilities, including upregulation of TLR expression or increased binding affinity of Toll-like receptors, or differentiation of monocytes to macrophages (Supplementary Results and Supplemental Figures IV, V). However, experiments demonstrated that at least 8 to 16 hours of exposure to THP-1 monocytes to SFA was required before the treatment amplified responses to LPS (data not shown). To test whether this time lag resulted from metabolic processing of PA by the monocytes, we examined the requirement for incorporation of PA into cells. The fatty acyl CoA synthetase inhibitor Triacsin-C significantly reduced the effect of PA on the LPS response ( Figure 2A ). We next assessed whether conversion of PA to its metabolic product ceramide, an important proinflammatory molecule implicated in the pathogenesis of insulin resistance, 26, 27 played a role in PA-mediated amplification of inflammation. As shown in Figure 2B , exposure of THP-1 monocytes to 100 mol/L PA for 16 hours significantly increased cellular C16 ceramide (the direct metabolic product of PA and the predominant ceramide in the monocytes). C18 ceramide content also increased significantly, although the increase was smaller. Furthermore, Triacsin-C also blocked PA-induced increases in C16 and C18 ceramide ( Figure 2B ), consistent with its inhibition of the amplified LPS response. Exposure of THP-1 monocytes to 50 mol/L C2 ceramide (a cell-permeable analogue of PA-derived C16 ceramide) similarly amplified LPS responses ( Figure 2C ). In contrast, the cell-impermeable C2 ceramide precursor C2 dihydroceramide did not amplify subsequent LPS responses. Inhibitors of different enzymatic steps in the conversion of PA to C16 ceramide (specifically, the serine palmitoyltransferase inhibitor Myriocin; the ketosphinganine synthetase inhibitor L-cycloserine; and the ceramide synthase inhibitor Fumonisin-B1) also effectively inhibited the ability of PA to enhance LPS-induced IL-6 and IL-8 expression ( Figure 2A ). Importantly, using C2 ceramide, but not C2 dihydroceramide, to bypass Triacsin-C restored the amplified responses to LPS ( Figure 2D ), demonstrating that Triacsin-C was not inducing nonspecific suppression of inflammation. Essentially identical results were observed when C2 ceramide was also used to bypass the other inhibitors of ceramide formation (data not shown). These data provide considerable evidence that generation of ceramide ). IL-6 (white bars) and IL-8 (black bars) mRNA was measured by real-time polymerase chain reaction. B, Cells were exposed to media or PA in the absence (PA) or presence (PA Triascin-C) for 16 hours. C16 (black bars) and C18 (white bars) ceramide concentrations were measured by mass spectrometry. C, Cells were exposed to media, LPS, C2 ceramide (C2), C2 dihydroceramide (diC2), or C2 or diC2 followed by LPS (C2 LPS or diC2 LPS). IL-6 and IL-8 mRNA was subsequently measured by real-time polymerase chain reaction. D, To determine whether ceramide could restore the amplified inflammation when ceramide synthesis was blocked using pharmacological inhibitors, C2 ceramide was also added to cells that had been treated with Triacsin-C. from SFA is required for SFA-induced amplification of TLR signaling, although they do not rule out contributions from other SFA metabolites.
Ceramides activate members of the protein kinase C (PKC) family. 28 In THP-1 monocytes exposed to PA, both conventional PKC and PKC-were activated (as measured by translocation to the cell membrane and phosphorylation on Ser411, respectively; Figure 3A ). Similar PKC activity was observed when cells were exposed to C2 ceramide but not to C2 dihydroceramide. Importantly, the activation of conventional PKC and PKC-was inhibited by Triacsin-C. Interestingly, the pan-conventional/ novel PKC inhibitor Calphostin-C did not inhibit amplification of the LPS response, and the potent pan-conventional/ novel PKC agonist PMA did not induce any synergistic amplification of THP-1 responses to LPS ( Figure 3B ). In contrast, exposure of monocytes to PA in the presence of an inhibitory PKC-pseudosubstrate peptide 29 inhibited the ability of PA to amplify monocyte proinflammatory gene expression in response to LPS, demonstrating the requirement for PKC-activity in this amplification mechanism.
Because PKC can serve as a potent mediator of cell signaling events via mitogen-activated protein kinase (MAPK) pathways, 30 we determined whether SFA activated MAPK signaling via ceramide-dependent and PKC--dependent pathways. Flow cytometry studies using activation state-specific antibodies to MAPK demonstrated that expo-sure of monocytes to PA induced activity of Erk1/2, JNK, and p38 ( Figure 4A) . Similarly, C2 ceramide also activated these same MAPK (Figure 4A , insets). We confirmed these flow cytometry results of PA-induced MAPK activation by Western blot techniques ( Figure 4B ). Importantly, the low concentrations of LPS (1 ng/mL) used in these experiments did not induce detectable JNK or p38 activity in the absence of PA, although some activation of Erk1/2 was observed in response to LPS. In addition, Western blots showed activation of JNK1 but not JNK2 in response to PA. Further experiments demonstrated that phosphorylation of Erk1/2, JNK, and p38 could be suppressed by PKC-inhibitor ( Figure 4C ) or by inhibitors of the metabolism of PA to ceramide (Supplemental Figure VI) . We also demonstrated PA-mediated activation of several MAPK-dependent transcription factors, including the AP-1 transcription factors c-Jun ( Figure 4B) , JunD, and c-Fos (not shown), and C/EBP-␣ and C/EBP-␤ ( Figure 4C ). PA-induced C/EBP activity was suppressed by the Erk1/2 inhibitor PD98059, the JNK inhibitor SP600125, or the p38 inhibitor SB202190, demonstrating this C/EBP activity is downstream of the MAPK. Importantly, the low concentration of LPS used in the present study did not induce phosphorylation of AP-1 or C/EBP transcription factors, in agreement with our findings that 1 ng/mL LPS had minimal ability to activate MAPK.
To confirm the necessity for MAPK activation in PAinduced amplification of TLR-mediated inflammation, exposure of monocytes to PD98059, SP600125, or SB202190 significantly reduced the ability of PA to amplify LPSinduced cytokine expression ( Figure 4D ). The combination of these MAPK inhibitors (each at a reduced concentration to avoid toxicity in combination) further reduced the ability of PA to amplify monocyte responses to LPS. Similar results were also obtained in freshly isolated primary human monocytes using SB202190 and SP600125 (Supplemental Figure IIB) , providing evidence that this same pathway may be relevant in vivo. Taken together, these results provide evidence that MAPK signaling is required for the SFA-amplified inflammation and suggest that ceramide derived from the metabolism of SFA leads to PKC-mediated activation of the MAPK.
Discussion
Work from several laboratories, 14, 31 including our own, 22 has demonstrated that SFA induces monocyte/macrophage inflammation, which appears mediated in part by TLR4signaling. The present study now demonstrates the novel finding that exposure of monocytes to elevated concentrations of SFA greatly amplifies the proinflammatory responses of these cells to TLR ligands though a separate TLR4independent pathway, dependent on the uptake and metabolic processing of SFA into ceramide.
Because elucidation of this pathway relied in part on the use of 4 pharmacological inhibitors of different enzymatic steps in the conversion of PA to ceramide, and because all inhibited amplification of the inflammatory response to LPS, it is highly unlikely that these results could be attributed to nonspecific inhibitor effects. Importantly, C2 ceramide could bypass the pharmacological inhibitors of SFA metabolism and augment the inflammatory action of LPS, further dem- 
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onstrating the specificity of the inhibitor effects and the importance of ceramide in this pathway. We also demonstrated activation of PKC-and MAPK signaling pathways when monocytes were exposed to PA, and we showed that inhibitors of ceramide synthesis also inhibited these pathways. Moreover, direct inhibition of PKC-and MAPK also attenuated the amplified inflammation. These data provide strong support for our hypothesis that SFA-enhanced inflammation is mediated by the conversion of SFA to ceramide and subsequent ceramide-mediated activation of PKC-mediated and MAPK-mediated signaling, and it is therefore unrelated to any ability of SFA to act as TLR2 or TLR4 ligands. 14, 15, 31 Experiments also demonstrated that PKC-inhibitor simultaneously inhibited PA-induced MAPK activity, providing strong evidence that MAPK lie downstream of PKC-. Although our data also showed activation of conventional PKC by PA and C2 ceramide, blockade of conventional PKC isoforms with Calphostin-C did not inhibit the ability of PA to amplify monocyte responses to LPS. Activation of conventional PKC using PMA also did not induce a synergistic amplification of the monocyte response to LPS. These data suggest conventional PKC does not contribute to the enhanced LPS response, but they do not rule out other roles for these enzymes.
As further evidence of MAPK involvement, we also confirmed that inhibitors of MAPK activity simultaneously reduced the SFA-stimulated activity of MAPK-dependent AP-1 and C/EBP transcription factors and the amplification of the LPS response. Additionally, these data may also provide insight into how MAPK activation could enhance LPS signaling. Several inflammatory cytokines, including IL-6 and IL-8, have promoter binding sites for members of the AP-1 and the C/EBP families, both of which have been reported to interact cooperatively with NF-B to upregulate gene expression. 32, 33 We speculate that the observed MAPK-mediated amplification of cytokine gene expression therefore may be affected via these same transcription factors enhancing the transcriptional effectiveness of LPS/ TLR4-induced NF-B activity.
This has several important implications because NF-B is widely recognized as a "master switch" of inflammation. 8 Therefore, we speculated that SFA may enhance transcription of a wide variety of inflammatory genes in a wide variety of cell types. Exposure of monocytes to PA amplified LPSinduced expression of several genes, including IL-1␤, IP-10, MCP-1, resistin, and tumor necrosis factor-␣, but not COX-2 (Supplemental Figure VII) , suggesting that this response is . PA-dependent activation of MAPK signaling is required for amplification of LPS responses. A and B, Monocytes were exposed to media alone (C and white histograms), 100 mol/L palmitic acid (PA and black histograms), or 1 ng/mL LPS. (Insets); monocytes were also exposed to media containing DMSO vehicle alone [white histograms]or media containing 50 mol/L C2 ceramide [black histograms]). Phosphorylation of p38, JNK1/2, and Erk 1/2 was measured by flow cytometry. B, Western blot also confirmed that exposure of monocytes to PA activated Erk1/2, JNK1, p38, and c-Jun in the presence and absence of LPS. Activation of the JNK-dependent transcription factor c-Jun was also measured. Beta-actin served as a loading control. C, Monocytes were exposed to control media (C), PA, or PA plus PKC-inhibitor (PAz), and phosphorylation of Erk1/2 (white bars), JNK (black bars), and p38 (striped bars) were measured by flow cytometry. D, Cells were exposed to PA and LPS plus inhibi- widespread among NF-B-mediated proinflammatory genes. This also raises the possibility that SFA may prime cells to amplify responses not only to LPS but also to a variety of other proinflammatory stimuli that activate NF-B. Consistent with this concept, we have also shown that exposure of monocytes to PA also amplifies their responses to the TLR2 ligand Pam3CSK4. Importantly, whereas siRNA-mediated knockdown of TLR4 does inhibit PA-amplified responses to LPS (the expected result because cells lacking TLR4 cannot respond to LPS), there is no inhibition of the ability of PA to amplify monocyte responses to the TLR2 ligand Pam3CSK4. This result clearly shows that PA-mediated amplified inflammation is not dependent on a specific TLR but must operate through a separate and more general mechanism. We illustrate in schematic form (Supplemental Figure VIII) the pathway that we believe our data suggest underlies this amplification.
The synergy between LPS and FFA was specific for SFA (PA, lauric acid, and stearic acid) and was not found when THP-1 monocytes were exposed to unsaturated FFA. In agreement with earlier reports, 15, 31 linoleic acid mildly suppressed the responses of monocytes to TLR ligands. Oleic acid neither amplified nor inhibited the responses of monocytes to LPS. This may be because of the preferential conversion of SFA to ceramide 34 or to the ability of unsaturated FFA to inhibit the underlying LPS-induced inflammation. 14, 31 However, the amplification effect was maintained for THP-1 cells and primary human monocytes when SFA were mixed with unsaturated FFA in physiological concentrations. These data are consistent with previous reports that SFA, but not unsaturated FFA, were proinflammatory. 14 -16,22,31 Although a previous report indicated that lauric acid was not directly capable of activating TLR-mediated signaling in mouse RAW296.7 macrophages, 16 this finding actually supports our interpretation that SFA-enhanced inflammation occurs via a novel mechanism independent of direct SFA/TLR interactions. Importantly, the present results were obtained in human cells while using fatty acids and LPS at plasma levels commonly found in individuals with obesity or type 2 diabetes, or after consumption of high-fat meals, [35] [36] [37] [38] [39] thereby providing evidence that the ability of SFA to amplify TLR signaling may have important physiological implications.
Consistent with this, our data also show that PA enhances the LPS response of macrophages as well as monocytes. Macrophage accumulation in tissue and production of proinflammatory cytokines are believed critical in development of insulin resistance, diabetes, and cardiovascular disease. We have previously demonstrated that cytokines released from macrophages induced adipocyte inflammation and reduced insulin action and lipolysis. 6 The resulting increase in FFA released from adipocytes can further enhance the macrophage-initiated proinflammatory cascade.
Several methodological considerations deserve mention. Although the present study is consistent with in vivo studies linking excess nutrition and elevated plasma SFA concentrations to inflammatory consequences, 16, 36, 40 our results were largely obtained using human cell lines. For this reason, the existence of this synergistic effect, its dependence on SFA uptake, and its dependence on MAPK activity were also confirmed ex vivo in primary human monocytes. The deci-sion to conduct these experiments with human cells and cell lines had advantages and disadvantages. Using human cells (monocytes and macrophages) provided considerably more weight to the potential relevance of this phenomenon to human disease. More importantly, whereas it might prove fruitful to examine specific signaling steps in this amplification pathway using mouse models in the future, initial experiments exposing mouse RAW296.7 macrophages to PA did not result in an amplified response to LPS (data not shown). These preliminary data suggested differences in responses between mouse and human cells, possibly reflecting well-known species differences in the sensitivity and specificity of human and murine TLR to certain ligands. 41 However, the necessity of using human monocytes limited the availability of genetically modified (eg, knockout) models and generally complicated the use of molecular methods. For example, whereas we successfully used siRNA to knock-down TLR4, our attempts to use siRNA against serine palmitoyltransferase consistently led to considerable cell death and a minimally effective knockdown in the remaining cells. Consistent with our experience, Tamehiro et al 42 still needed to use Myricin to achieve substantial inhibition of ceramide synthesis even in THP-1 cells selected (using puromycin) for successful transfection and expression of lentiviral shRNA against this enzyme. To overcome these difficulties, we studied this pathway using multiple, functionally unrelated inhibitors.
In conclusion, this study presents the novel finding that SFA can greatly amplify the inflammatory responses of monocytes/macrophages to LPS via TLR4-independent mechanisms. These data suggest that uptake of SFA leads to enhanced ceramide generation, which in turn activates PKCand MAPK. Concentrations of SFA and LPS that are commonly present in conditions resulting from excess nutrition (eg, obesity, insulin resistance, type 2 diabetes, etc) and high-fat diets can lead to inflammation that is several-fold greater than the direct proinflammatory effects of each of these factors alone. The elevation of SFA and LPS in these settings could create a "perfect storm" of factors leading to greatly increased monocyte/macrophage innate immune responses. Because monocytes/macrophages are critical cells mediating tissue and systemic inflammation, a broad and "synergistic" amplification of their inflammatory activity by SFA may be an important contributor to the genesis or progression of insulin resistance and type 2 diabetes, as well as the cardiovascular sequelae of these conditions.
